Here we tested whether the efficacy of the EGFR-TKI erlotinib can be enhanced and resistance of NSCLC cells to this drug be overcome by combining it with the highly specific KCa3.1 inhibitor senicapoc. This evidence concerns the gene EGFR and non-small cell lung carcinoma.